TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $23.00 million which beat the analyst consensus estimate of $22.11 million by 4.03 percent. This is a 114.94 percent increase over sales of $10.70 million the same period last year.
Barclays Upgrades Warner Music Group to Overweight, Raises Price Target to $48
Barclays analyst Kannan Venkateshwar upgrades Warner Music Group (NASDAQ:WMG) from Equal-Weight to Overweight and raises the price target from $38 to $48.
